Results for tag: "Sipuleucel T"

Sipuleucel-T is a type of immunotherapy drug used to treat prostate cancer. It is a personalized cellular therapy, meaning it is made from a patient's own immune cells. The drug works by stimulating the patient's immune system to recognize and attack prostate cancer cells. It is administered through a series of three intravenous infusions over the course of several weeks. Sipuleucel-T is approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is the only FDA-approved immunotherapy for prostate cancer. The market for Sipuleucel-T is relatively small, as it is only approved for a specific type of prostate cancer. However, it is an important treatment option for patients with this type of cancer. Companies in the Sipuleucel-T market include Dendreon Corporation, which manufactures the drug, as well as other pharmaceutical companies that market and distribute it. Show Less Read more